Sharlene Gill, Medical Oncologist and Medical Director, Staff Wellness and Engagement at BC Cancer, shared a post on X:
“Practice-changing ALASCCA ph3 trial
ASA 160mg in PIK3CA+ stage II-III CRC
PIK3CA+ in 37%
HR 0.42 for 3yr DFS!”
Sharlene Gill, Medical Oncologist and Medical Director, Staff Wellness and Engagement at BC Cancer, shared a post on X:
“Practice-changing ALASCCA ph3 trial
ASA 160mg in PIK3CA+ stage II-III CRC
PIK3CA+ in 37%
HR 0.42 for 3yr DFS!”
